pipette
ENEnglish

Causal relationship between liver fat reduction and clinical outcomes in human genetic studies and randomized clinical trials of metabolic-dysfunction associated steatohepatitis

N. Verweij, G. Hindy, Q. Nguyen, O. Sosina, K. A. Mohammadi, T. Bedi, J. Herman, K. Landheer, B. Geraghty, S. Somersan-Karakaya, A. Locke, L. Ganel, A. Gilly, R. Lanche, S. Hectors, M. Germino, G. H. Imperato, I. Anidi, L. Choleva, E. Labriola-Tompkins, M. Effendi, K. Tuckwell, S. Aziz-Zaman, J. Witkin, J. L. Miller, T.-H. Schwantes-An, Regeneron Genetics Center, GHS-RGC DiscovEHR Collaboration, Penn Medicine Biobank, Colorado Center for Personalized Medicine, Mayo Clinic-RGC Project Generation, Malmo Diet and Cancer Study, Indiana University School

PreprintUso en el mundo real

En palabras de los autores

Reliance on invasive liver biopsy endpoints is a major limiting factor in new therapeutic development for metabolic dysfunction-associated steatohepatitis (MASH). While liver fat accumulation is considered a driver of early disease, liver fat reduction is not recognized as a surrogate endpoint by health authorities. Here, we conducted the largest-to-date genome-wide association study (GWAS) of liver fat in 79,642 people with magnetic resonance imaging and developed a polygenic score with liver fat-lowering alleles across 55 genomic loci. In a separate set of 714,886 individuals, a 30% relative liver fat reduction due to the polygenic score was associated with 39% lower odds of liver cirrhosis and 41% lower odds of hepatocellular carcinoma, consistent with a strong causal relationship between lifelong liver fat differences and advanced liver clinical outcomes. A systematic review and meta-analysis of 20 randomized controlled trials including a total of 3,502 MASH patients showed that treatment-induced liver fat reductions were associated with MASH resolution (meta-regression slope in % units of the outcome for each 1% relative reduction in liver fat from baseline, {beta} = -0.70%, p<0.001) and fibrosis improvement ({beta} = -0.24%, p<0.001). These findings demonstrate the profound etiologic impact of liver fat in MASH and provide compelling evidence for liver fat reductions as a reasonably likely surrogate endpoint for future clinical development.

Resultado principalEl resumen no menciona limitaciones.

En palabras simples Resumen con IA

También analizaron 20 ensayos de medicamentos con 3,502 pacientes con MASH. Cada reducción del 1% en grasa hepática inducida por medicamentos se vinculó con mejores marcadores de la enfermedad. Los autores concluyen que la reducción de grasa hepática es un sustituto razonablemente probable del verdadero beneficio clínico en futuros ensayos.

Escrito por Kimi K2.5 usando solo el abstract de arriba. Jev verificó que cada oración esté respaldada por las oraciones del abstract que cita y eliminó las que no. Pasá el cursor por una oración para ver de dónde sale. Se eliminaron 2 oraciones por no estar respaldadas por el abstract.

Apareció: martes, 29 de septiembre. medRxiv. Preprint, todavía sin revisión por pares.

DOI: 10.64898/2026.09.27.26364101